NATCO Pharma Balance Sheet Health
Financial Health criteria checks 6/6
NATCO Pharma has a total shareholder equity of ₹71.6B and total debt of ₹2.0B, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are ₹82.4B and ₹10.9B respectively. NATCO Pharma's EBIT is ₹21.9B making its interest coverage ratio -27.4. It has cash and short-term investments of ₹24.6B.
Key information
2.8%
Debt to equity ratio
₹2.01b
Debt
| Interest coverage ratio | -27.4x |
| Cash | ₹24.63b |
| Equity | ₹71.57b |
| Total liabilities | ₹10.88b |
| Total assets | ₹82.45b |
Recent financial health updates
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Recent updates
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02Financial Position Analysis
Short Term Liabilities: NATCOPHARM's short term assets (₹50.0B) exceed its short term liabilities (₹10.1B).
Long Term Liabilities: NATCOPHARM's short term assets (₹50.0B) exceed its long term liabilities (₹792.0M).
Debt to Equity History and Analysis
Debt Level: NATCOPHARM has more cash than its total debt.
Reducing Debt: NATCOPHARM's debt to equity ratio has reduced from 8.2% to 2.8% over the past 5 years.
Debt Coverage: NATCOPHARM's debt is well covered by operating cash flow (853.9%).
Interest Coverage: NATCOPHARM earns more interest than it pays, so coverage of interest payments is not a concern.